CLINICAL TRIAL article
Front. Pharmacol.
Sec. Ethnopharmacology
This article is part of the Research TopicTreating Hepato-Intestinal Diseases with Herbal Medicines and their MetabolitesView all 9 articles
Clinical efficacy and metabolomics profiling of Dachaihu Decoction for patients with septic liver injury: A randomized controlled trial
Provisionally accepted
- Guangzhou University of Chinese Medicine, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Septic liver injury (SLI) is a life-threatening complication of sepsis with limited therapeutic options. The clinical efficacy and safety of Dachaihu Decoction (DCHD) in SLI remain to be elucidated. Methods and design: A prospective, single-center, single-blind, randomized, and placebo-controlled clinical trial was conducted. Patients in the DCHD group received DCHD twice a day for five consecutive days on the basis of sepsis bundle, while patients in the placebo group were administered a placebo in the same dose as the DCHD. Primary outcomes included: (1) liver function indices: alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBil); (2) Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores; (3) 28-day all-cause mortality. Secondary outcomes included the evaluation of several clinical parameters: (1) infection indicators; (2) coagulation indicators; (3) gastrointestinal function indicator; (4) metabolic and respiratory function indicators. Subsequently, We employed Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to characterize the serum metabolomics profiling of two groups of patients. Results: DCHD significantly reduced TBil (-22.50 (interquartile range, IQR, -37.20, -8.10) vs. -3.30 (-17.16, 12.40), p < 0.001), SOFA score (-2.46 ± 2.84 vs. -1.11 ± 2.71, p = 0.047), APACHE II score (-5 (IQR, -5, -2) vs. -2 (-5, 2), p = 0.034), and Oxygenation Index (OI) (29.71 ± 74.76 vs. -15.16 ± 108.51, p = 0.048). However, no statistically significant difference in 28-day all-cause mortality was found between the DCHD and the placebo groups (7 (20.0%) vs. 9 (25.7%), p = 0.569). Additionally, our study demonstrates that DCHD ameliorates systemic infection, coagulation function, gastrointestinal function, and metabolic function in patients to a certain extent, and the incidence of nonfatal adverse events was lower in the DCHD group (2 (5.71%) vs. 4 (11.43%), p =0.673). Metabolomics analysis reveals that Wogonin, Wogonoside, Cholic acid, and Glycocholic acid are representative differential metabolites, and bile acid metabolism may be the core metabolic pathway. Conclusion: As an adjunctive therapy, DCHD demonstrates safety and efficacy in the treatment of SLI, particularly cholestatic hepatic dysfunction, which may be intimately linked to its modulation of bile acid metabolism. Clinical Trial Registration: http://itmctr.ccebtcm.org.cn, ITMCTR2025000095.
Keywords: Septic liver injury, dachaihu decoction, randomized controlled trial, Traditional Chinese Medicine, Metabolomics
Received: 23 Jul 2025; Accepted: 29 Oct 2025.
Copyright: © 2025 Yang, Kao, Zhu, Lei, Huang, Chen, He, Lin and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mingfeng He, he-mingfeng@foxmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.